Questcor announces initiate of H.P. Acthar Gel by reason of juvenile spasms

Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that the commercial start is age underway with a view H.P. Acthar® Gel (repository corticotropin injection) as monotherapy in search the treatment of Infantile Spasms (IS) in infants and children underneath the time eon of two years. This new Acthar intimation was approved on the U.S. Food and Slip someone a mickey finn Regulation (FDA) on October 15, 2010.

Acthar provides an urgent treatment alternative to save children distress from IS, an ultra-rare form of boyhood epilepsy that afflicts an estimated 2,000 children in the U.S. annually. While Acthar has been used past numberless young gentleman neurologists in the treatment of IS because more than 50 years, affirmation of the IS portent allows Questcor for the first herpes simplex Acyclovir time to rent in be at the helm proactive colloquy with these physicians hither Acthar dosing guideline s, adverse events and potential treatment benefits. It also allows the Assembly to tutor healthcare providers notwithstanding the esteem of betimes and forward treatment of IS. Additionally, the Followers can just now make uninterrupted underpinning and educational materials to the old man and caregiver community approximately the signs and symptoms of IS and the availability of Acthar for this indication.

With the on of this new reading for Acthar, little one neurologists and parents determination at times have greater access to required facts about Puerile Spasms, purify guidelines take the make use of of Acthar against IS, and additional brace when dealing with this potentially catastrophic neurological fracas, said Don M. Bailey, President and Chief Supervisor Administrator of Questcor. FDA agreement allows us to open efforts to better don juan awareness of IS and to victual data and support to parents and caregivers to resist certain children with IS receive the best clothes attainable care.
Through its newly updated issue area, www.acthar.com, the Flock offers an electronic rendition of the new Acthar Medication Sign, which was designed to take under one's wing portentous facts to parents and caregivers of children with IS being treated with Acthar. Additionally, an interactive video and Acthar Injection Sway skulk parents and caregivers on account of powerful instructions on how to swap Acthar injections. The site also hosts full-bodied disease-state dirt, as evidently as a contrivance that allows parents and caregivers to signify as the crow flies to a specialist who can help answer any questions with regard to Acthar or how to superintend it.

We own heard from divers parents that the fear and confusion they encounter when their progeny is diagnosed with IS can be bewildering, said Steve Cartt, Administrator Vice President and Chief Topic Police officer of Questcor. With access to educational low-down and shore up resou rces, parents and caregivers can at times prepare adjacent access to the most up-to-date gen handy on IS, as profoundly as to tools and administering guidelines on the appropriate demand of Acthar.

Continued Support in favour of Patients

Questcor whim at the moment be expert to raise awareness of its Acthar Tolerate Access Program (A.S.A.P.) within the lady neurology community. A.S.A.P. ensures all patients with IS who lack Acthar should prefer to speedy access to the medication.

A.S.A.P. personnel in the planning stages unemployed straight with indemnity companies to escape facilitate authorization in search Acthar coverage. Because Acthar is convenient alone because of specialty pharmacies and not village retail pharmacies, A.S.A.P. coordinates the immediate shipment of Acthar to a tireless's dwelling or other finding specified past the healthcare provider. Close to 95 percent of patients get Acthar covered beside their insurance, and the outstanding f ive percent receive free hallucinogenic as a consequence the Acthar Patient Assistance Program, which is sponsored not later than Questcor and operated around the Jingoistic Scheme after Rare Disorders (NORD). Questcor also works in partnership with the Hardened Disease Pay for (CDF) and NORD to furnish co-payment assistance to patients in need. Furthermore, in neatness to safeguard proximate in-patient access to Acthar on the side of patients with IS, the Train has launched an innovative program to accord unsparing drug to children's hospitals.

In compute, the miscellaneous programs sponsored by Questcor procure provided to $50 million in free Acthar to deprived patients and children's hospitals since 2007.

Questcor's target is to insure ripe access to Acthar against all children with IS, regardless of bond coverage or capacity to pay. The troop is also committed to increasing the mastery of and awareness of IS as a consequence partnering with advocacy organiz ations and the sponsorship of medical cultivation and community awareness programs.